









Markets
/
Stocks
/
nasdaq-atyr
/

aTyr Pharma Inc

ATYR

0.899USD

+0.088+10.89%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

88.09MMarket Cap

LossP/E TTM



aTyr Pharma Inc

0.899

+0.088+10.89%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of aTyr Pharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

aTyr Pharma Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.36.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

aTyr Pharma Inc's Score

Industry at a Glance

Industry Ranking

75 / 392

Overall Ranking

196 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

aTyr Pharma Inc Highlights

StrengthsRisks

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Growing

The company is in a growing phase, with the latest annual income totaling USD 235.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 235.00K.

Overvalued

The company’s latest PE is -1.08, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 62.14M shares, decreasing 0.01% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.96M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.87.

Analyst Rating

Based on 10 analysts

Hold

Current Rating

6.357

Target Price

+621.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of aTyr Pharma Inc is 6.87, ranking 194 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.87

Change



Financials

5.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.09

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.48

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

aTyr Pharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of aTyr Pharma Inc is 7.36, ranking 130 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.08, which is -27.54% below the recent high of -0.78 and -674.11% above the recent low of -8.34.

Score

Industry at a Glance

Previous score

7.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of aTyr Pharma Inc is 6.80, ranking 326 out of 392 in the Biotechnology & Medical Research industry. The average price target is 1.00, with a high of 20.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Hold

Current Rating

6.357

Target Price

+621.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

aTyr Pharma Inc

ATYR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of aTyr Pharma Inc is 8.76, ranking 59 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.07 and the support level at 0.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.11

Change

1.65

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.036

Buy

RSI(14)

59.414

Neutral

STOCH(KDJ)(9,3,3)

57.411

Neutral

ATR(14)

0.088

High Vlolatility

CCI(14)

56.700

Neutral

Williams %R

38.118

Buy

TRIX(12,20)

0.768

Sell

StochRSI(14)

34.835

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.904

Sell

MA10

0.834

Buy

MA20

0.773

Buy

MA50

0.763

Buy

MA100

0.821

Buy

MA200

2.807

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of aTyr Pharma Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.65%, representing a quarter-over-quarter decrease of 0.54%. The largest institutional shareholder is The Vanguard, holding a total of 4.96M shares, representing 5.06% of shares outstanding, with 12.49% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

14.70M

+10.09%

Federated Hermes Global Investment Management Corp.

10.54M

-28.11%

BlackRock Institutional Trust Company, N.A.

5.98M

+11.89%

The Vanguard Group, Inc.

Star Investors

5.63M

+20.96%

State Street Investment Management (US)

4.20M

+238.49%

GSA Capital Partners LLP

706.73K

+42.40%

Geode Capital Management, L.L.C.

2.18M

+3.82%

Millennium Management LLC

1.89M

+18.17%

UBS Financial Services, Inc.

4.34M

+148.61%

Schimmel (Paul R Ph.D.)

1.10M

+9.99%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of aTyr Pharma Inc is 3.26, ranking 159 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.